Hepatitis C virus (HCV) is known as a “silent epidemic” because a large proportion of individuals living with HCV are asymptomatic or have mild symptoms and do not seek medical care. The Centers for Disease Control and Prevention (CDC) estimates that for every reported HCV infection there are 13.9 undiagnosed cases. The rise in HCV infections, particularly among younger demographics, is driven by injection drug use (IDU). Challenges in controlling the impact of HCV include low screening, treatment initiation rates, and patient education, particularly among high-risk and medically underserved populations.
In this CME Outfitters Live and OnDemand webcast, expert faculty will discuss the many barriers to treating HCV in the IDU population, including stigma and established negative perceptions about people who inject drugs (PWID), with special attention paid to applying CDC universal screening guidelines to improve diagnosis and linkage to treatment, expanding treatment for HCV in primary care settings, and addressing disparities in HCV treatment initiation in underserved communities.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, emergency medicine clinicians, addiction specialists, nurse practitioners, PAs, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Younossi reports that he receives research support from Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; and Siemens. He is a consultant for Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Siemens; and Terns Pharmaceuticals, Inc.
Dr. Cave reports that she receives grants from Gilead Sciences, Inc. She is on the speakers bureau and advisory board for AbbVie Inc. and Gilead Sciences, Inc.
Dr. Martinez reports that he receives research support from AbbVie Inc.; Allergan; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc. He is on the speakers bureau for AbbVie Inc.; Eisai Inc.; and Gilead Sciences, Inc. He is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.
Dr. Ramers reports that he receives grants from AbbVie Inc. and Gilead Sciences, Inc. He receives research support from Gilead Sciences, Inc. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; and Viiv Healthcare. He is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; and Theratechnologies Inc.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-113-H01-P
Call us at 877.CME.PROS (877.263.7767).